Determination of 3H-thymidine incorporation into ovarian cancer cells and its validity with regard to cytostatic therapy

The incorporation of 3H-thymidine in ovarian cancer cells determined by autoradiography represents a method of additional tumor characterization. The in vitro tests allowed roughly hints about the efficiency of an intended therapy in 49 patients suffering from ovarian cancer. High risk patients ought to be excluded from chemotherapy, if the incorporation of thymidine is low. For this decision the results of oncobiograms and clinical parameters were evaluated. The 3H-thymidine incorporation enables to select an individual kind of therapy for any patient with regard to success and duration of treatment. (author)